European Registry of Next Generation Imaging in Advanced Prostate Cancer

Launched by FUNDACIO PUIGVERT · Mar 4, 2025

Keywords

ClinConnect Summary

The European Registry of Next Generation Imaging in Advanced Prostate Cancer, also known as the RING study, is looking to gather information on how advanced imaging techniques, like PET scans and whole-body MRIs, can help in detecting and monitoring prostate cancer. This study aims to compare these newer imaging methods with traditional ones to see how they influence treatment choices and patient outcomes.

Men aged 18 and older who have been diagnosed with prostate cancer and need imaging to check for cancer spread may be eligible to participate. Participants will continue to receive standard medical care without any experimental treatments. They will need to sign a consent form to join the study. The goal is to better understand when these advanced imaging techniques should be used and how they can potentially improve the management of prostate cancer.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult male patients (≥18 years with no upper age limit).
• • 2. Histologically proven prostate cancer.
• • 3. Patients who require imaging exploration (conventional, Next-Generation Imaging (NGI), or their combination) at high risk for harbouring metastatic deposits at the hormone-sensitive stage, either at the diagnostic workout of a "naïve" patient or at biochemical relapse/progression after local treatment.
• • 4. Patients who authorize their participation in the study by signing a written informed consent form (ICF).
• Exclusion Criteria:
• • 1. Patients participating in other interventional or non-interventional study which requires NGI as a triage test for metastatic assessment.
• • 2. Patients with evidence of any other clinically significant disease or condition which in the opinion of the investigator discourages their participation in the study.
• • 3. Patients who will not be able to complete the study.